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Abstract
The SNF2-related CBP activator protein (SrCap) is a potent activator of transcription mediated by CBP and CREB. We have previously
demonstrated that the Adenovirus 2 DNA Binding Protein (DBP) binds to SrCap and inhibits the transcription mediated by the
carboxyl-terminal region of SrCap (amino acids 1275–2971). We report here that DBP inhibits the ability of full-length SrCap (1–2971) to
activate transcription mediated by Gal-CREB and Gal-CBP. In addition, DBP also inhibits the ability of SrCap to enhance Protein Kinase
A (PKA) activated transcription of the enkaphalin promoter. DBP was found to dramatically inhibit transcription of a mammalian
two-hybrid system that was dependent on the interaction of SrCap and CBP binding domains. We also found that DBP has no effect on
transcription mediated by a transcriptional activator that is not related to SrCap, indicating that our reported transcriptional inhibition is
specific for SrCap and not due to nonspecific effects of DBP’s DNA binding activity on the CAT reporter plasmid. Taken together, these
results suggest a model in which DBP inhibits cellular transcription mediated by the interaction between SrCap and CBP.
© 2003 Elsevier Science (USA). All rights reserved.
Introduction
The cyclic-AMP responsive element-binding protein
(CREB) regulates the transcription of several genes (Daniel
et al., 1998; Montminy, 1997). CREB targets these genes by
binding to the sequence-specific cyclic-AMP responsive
element (CRE) found in many promoters. An increased
level of cAMP stimulates gene expression from CRE-con-
taining promoters. The increase in transcription is largely
due to phosphorylation of CREB at serine 133 by cAMP-
activated Protein Kinase A (PKA) (Shaywitz and Green-
berg, 1999). Phosphorylation of CREB by PKA facilitates
the association of CREB with the CREB-binding protein,
CBP (Chrivia et al., 1993; Kwok et al., 1994). CBP is
critical for CREB-mediated transcriptional activation (Kor-
zus et al., 1998). Studies to determine what regions within
CBP were important for it to function as a CREB coactiva-
tor led to the identification of a transcriptional activation
domain defined within amino acids 227–460 (Swope et al.,
1996), shown in Fig. 1A. This region overlaps a region of
CBP (amino acids 1–450) that has been shown to interact
with the Adenovirus (Ad) E1A proteins (Kurokawa et al.,
1998) and is distinct from the CREB binding domain within
CBP located within amino acids 586–666 (Radhakrishnan
et al., 1997).
Our previous studies utilizing CBP amino acids 227–460
as bait in a yeast two-hybrid screen led to the identification
of a novel gene product that binds to CBP. This protein
shares structural features with proteins in the SNF2 protein
family, most notably seven regions that collectively com-
prise a functional ATPase domain (Johnston et al., 1999)
(see Fig. 1B). The SNF2 protein family are involved in
chromatin remodeling, DNA repair, and transcriptional reg-
ulation (Sudarsanam and Winston, 2000). Since we have
demonstrated that this protein can enhance the ability of
CBP to activate transcription, we have called it SrCap
(SNF2-related CBP activator protein). In a more recent
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study, we have demonstrated that SrCap serves as a coac-
tivator for the transcription factor CREB, which is known to
interact with CBP (Johnston et al., 1999; Monroy et al.,
2001).
Among a wide variety of transcription factors that phys-
ically interact with CBP at several separate and defined
regions (Daniel et al., 1998; Goldman et al., 1997; Mont-
miny, 1997), both SrCap and the E1A proteins were shown
to bind to overlapping regions on CBP (see Fig. 1A)
(Johnston et al., 1999; Kurokawa et al., 1998). The binding
of the E1A proteins to CBP and to the closely related
protein family member, p300, are both strongly implicated
in the ability of E1A to activate cell growth and to repress
differentiation and tissue-specific transcription (Moran,
1994). We have demonstrated that wild-type E1A, but not
an E1A mutant unable to bind CBP/p300, inhibits transcrip-
tion in a mammalian two-hybrid CAT assay that is depen-
dent on the interaction between the SrCap and CBP binding
regions. The apparent competitive inhibition of the binding
interaction between SrCap and CBP by E1A in this system
represents a possible mechanism that may contribute to
E1A-mediated transcriptional repression (Johnston et al.,
1999).
In the course of these studies on the effect of adenovirus
gene expression on SrCap, we found that the Ad 2 DNA
Binding Protein (DBP) binds to SrCap and strongly inhibits
SrCap-mediated transcriptional activity (Xu et al., 2001).
DBP is a 529 amino acid protein that binds to both single-
and double-stranded DNA and RNA (Cleghon and Klessig,
1986; Neale and Kitchingman, 1990). In vitro studies have
shown that DBP can function in the initiation and elonga-
tion phases of DNA replication, suggesting an in vivo model
that DBP functions to unwind double-strand viral DNA by
multimerizing along the displaced single-stranded viral
DNA (Shenk, 1996). DBP is also tightly involved in other
essential functions important in the adenovirus life cycle,
including viral RNA stability (Cleghon et al., 1989), virus
assembly (Nicolas et al., 1983), determination of virus host
range (Anderson et al., 1983), and transformation (Rice et
al., 1987).
In addition, DBP is implicated in transcriptional regula-
tion. With the exception of the adenovirus E4 promoter,
which is slightly inhibited by DBP, DBP generally activates
transcription from viral promoters. These include the ade-
novirus E1A, E2A, and major late promoters, and the ad-
eno-associated virus P5 promoter (Chang and Shenk, 1990).
In the major late promoter and P5 promoter, DBP increases
transcription by enhancing the binding affinity of a tran-
scription factor (termed upstream stimulatory factor 1
(USF1), and also known as the major late transcription
factor (MLTF)), to its associated binding site present in both
promoters (Zijderveld et al., 1994). DBP also enhances the
ability of the transcription/replication factor, NF1, to bind to
its associated DNA recognition site in the adenovirus origin
of replication (Stuiver and van der Vliet, 1990). This ability
of DBP to enhance the affinity of transcription factors for
their cognate recognition sites may represent a mechanism
of DBP-mediated activation of transcription. While DBP
has been shown to activate several viral promoters, the
effects of DBP on cellular promoters have not been re-
ported. This is an interesting question because, similar to the
E1A’s abilities to both activate and repress gene expression
(Moran and Mathews, 1987), DBP may also contribute to a
reduction of at least a subset of host cell gene expression
while activating viral gene expression.
Given our previous observation that DBP binds to SrCap
and strongly inhibits SrCap-mediated transcription (Xu et
al., 2001), and considering that SrCap is a coactivator of
CBP (Johnston et al., 1999; Monroy et al., 2001), we tested
whether DBP is able to influence transcription of the CBP
and CREB-responsive cellular enkephalin promoter.
Results and discussion
DBP inhibits SrCap-dependent activation of the
PKA/CREB-activated enkephalin promoter
To test whether DBP has any effect on PKA-activated
CREB-mediated transcription, we transfected CHO cells as
described previously (Xu et al., 2001) with a CAT reporter
construct containing the enkephalin promoter, pEnk12-
CAT. This promoter contains two cyclic-AMP responsive
elements and has been used by others to study CREB-
mediated transcription (Huggenvik et al., 1991). Also trans-
fected were one or more of the following plasmids: pRc/
RSV-CREB, a plasmid that expresses the CREB protein
(Walton et al., 1992); pPKA, a plasmid that expresses the
catalytic subunit of protein kinase; pSrCap(1–2971); and
pcDNA-DBP. As shown in Fig. 2, cotransfection of plas-
Fig. 1. Diagram of SrCap, E1A, and CREB protein binding regions on CBP
(A), and CBP and DBP protein binding regions on SrCap (B). Numbers
indicate the amino acid boundaries of the indicated protein binding regions.
Filled boxes indicate the regions of SrCap that are homologous to the SNF2
regions that comprise the ATPase domains. Additional functional and
protein binding regions for CBP can be found in Goodman and Smolik
(2000) and for SrCap in Johnson et al. (1999).
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mids expressing PKA and CREB, or PKA and CREB with
SrCap, activated transcription 4- and 12-fold, respectively.
The PKA-mediated enhancement of CREB-mediated tran-
scription is presumably due to PKA phosphorylation of
CREB at residue 133, which facilitates the association of
phospho-CREB with endogenous CBP to activate transcrip-
tion. Endogenous SrCap probably also participates in this
transcriptional activation, given that exogenously expressed
SrCap has a strong activation effect. When a plasmid ex-
pressing DBP was cotransfected with plasmids expressing
PKA and CREB with SrCap, the observed transcriptional
activation was reduced from 12- to 7.3-fold. Thus, DBP
inhibits the effect of exogenously expressed SrCap on PKA-
CREB-CBP-mediated transcription in the context of a cel-
lular promoter. In the absence of exogenously expressed
SrCap, DBP reduced PKA and CREB-mediated activation
from 4- to 2.4-fold. Presumably, this represents DBP inter-
ference with endogenous SrCap. It appears that DBP plays
a role in both the activation of virus genes and the inhibition
of host cell genes. Similar results were obtained when these
assays were performed in HeLa cells (data not shown).
To address the possibility that DBP-mediated inhibition
of enkephalin promoter activity is not due to promoter-
specific effects, such as DBP interaction with a PKA-stim-
ulated transcription factor other than CREB, we asked
whether DBP could also inhibit the transcription activity
induced by a Gal–CREB fusion protein from pGal-CAT, a
CAT reporter plasmid that contains a Gal4 responsive ele-
ment.
DBP inhibits SrCap-activation of Gal-CREB-mediated
transcription
CHO cells were transfected with the reporter plasmid
pGal-CAT, plus pGal-CREB, a plasmid that expresses the
CREB protein fused with the Gal4 DNA-binding domain
(Kwok et al., 1994). The transfected plasmid set variously
included pPKA, pSrCap(1–2971), and pcDNA-DBP. As
shown in Fig. 3, PKA enhanced Gal-CREB-mediated tran-
scription 4.7-fold. The addition of full-length SrCap further
activated PKA-enhanced Gal-CREB-mediated transcription
to 7.5-fold. These results are consistent with those previ-
ously reported (Monroy et al., 2001). However, in the pres-
ence of DBP, PKA-enhanced Gal-CREB-mediated tran-
scription was reduced from 4.7- to 1.9-fold. Activity in the
presence of SrCap was reduced from 7.5- to 5.2-fold. These
data suggest that DBP-mediated inhibition is not specific to
the promoter element, but is an effect on the transcription
complex containing CREB, CBP, and SrCap.
DBP inhibits SrCap-activated Gal-CBP-mediated
transcription
To test the hypothesis that DBP inhibits transcription via
impairment of the CBP-SrCap interaction, we tested
Fig. 3. DBP inhibits SrCap-activation of Gal-CREB-mediated transcrip-
tion. CHO cells were transfected as indicated with 100 ng of pGal-CAT
reporter plasmid, 100 ng of a plasmid encoding a Gal-CREB chimera
(pGal-CREB), 25 ng of a plasmid encoding the catalytic subunit of PKA
(pPKA) as indicated, 2000 ng of a plasmid encoding SrCap (pSrCap), and
250 ng of a plasmid encoding Adenovirus DBP (pcDNA-DBP) as indi-
cated. The relative CAT enzymatic activity was determined by dividing the
CAT enzymatic activity of each sample by the transcriptional activity
induced by the Gal-CREB chimera (which was assigned a relative value of
1). Values represent the means  SE from at least two separate experi-
ments in which each sample was assayed in triplicate.
Fig. 2. DBP inhibits SrCap-activation of the PKA/CREB-activated CRE-
containing promoter. CHO cells were transfected as indicated with 100 ng
of pEnk12-CAT reporter plasmid, 100 ng of a plasmid encoding CREB
(pCREB), 50 ng of a plasmid encoding the catalytic subunit of PKA
(pPKA), 2000 ng of a plasmid encoding full-length (FL) SrCap (pSr-
Cap(FL)), and 250 ng of a plasmid encoding Adenovirus DBP (pcDNA-
DBP). The relative CAT enzymatic activity was determined by dividing the
CAT enzymatic activity of each sample by the transcriptional activity
induced by the pEnk 12-CAT (which was assigned a relative value of 1).
Values represent the means  SE from at least two separate experiments
in which each sample was assayed in triplicate.
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whether DBP could inhibit the ability of SrCap to activate
transcription of a Gal-CBP chimera in a system that does
not require CREB. CHO cells were transfected with the
pGal-CAT reporter plasmid plus pGal-CBP, which ex-
presses full-length CBP fused with the Gal4-DNA binding
domain (the plasmids are described in Monroy et al. 2001).
One set of transfected cells also received pSrCap(1–2971).
Transcription activity in this system was measured in the
presence and absence of pcDNA-DBP. In Fig. 4, we ob-
served that DBP expression reduced the ability of the Gal-
CBP chimera to activate transcription by 30%. A similar
reduction of activity was observed in the SrCap-transfected
cells. These results are consistent with the suggestion that
DBP functions by disrupting the CBP–SrCap interaction.
To test this hypothesis, we asked directly whether DBP
could functionally inhibit the interaction between CBP and
SrCap.
DBP disrupts the interaction between SrCap and CBP
To test whether DBP can functionally disrupt the SrCap–
CBP interaction, we used a mammalian two-hybrid CAT-
reporter system designed to function through the SrCap and
CBP interaction domains (Johnston et al., 1999). This two-
hybrid system was originally used to demonstrate that E1A
could disrupt the CBP–SrCap functional interaction (John-
son et al., 1999). CHO cells were transfected with the
pGal-CAT reporter plasmid, plus pGal-CBP (280–460),
which expresses the SrCap-binding domain of CBP, plus
pVP16-SrCap (1380–1729), which contains the CBP-bind-
ing domain of SrCap (Johnston et al., 1999). The transfec-
tion system was tested, with or without pcDNA-DBP. As
shown in Fig. 5, VP16-SrCap (1380–1729) activated tran-
scription mediated by pGal-CBP (280–460) 26-fold. Addi-
tion of DBP blocked this activity in a dose-dependent man-
ner, indicating that DBP disrupts the interaction of SrCap
and CBP. The ability of DBP to slightly inhibit transcription
in the absence of VP16-SrCap (1380–1729) is presumably
due to a functional disruption of the interaction between
endogenous SrCap and Gal-CBP (280–460).
To distinguish between the possibilities that the inhibi-
tion is due to a direct effect of DBP interacting with SrCap
or some aberrant interaction of DBP with the Gal4 portion
of the fusion protein or a direct interaction of DBP’s DNA-
binding activity with the CAT reporter plasmid, we tested
whether DBP could inhibit a transcription factor that was
unrelated to SrCap.
DBP has no effect on the transcriptional activity of a
transcriptional activator that is not related to SrCap
To determine whether DBP affected the transcription
activity of a known transcriptional activator that is not
related to the SrCap protein, we tested whether DBP could
regulate the FOXC1 transcriptional activator. FOXC1 is a
member of the Forkhead Box family of transcription factors
that share a 110 amino acid DNA binding domain that is
located roughly within amino acids 78–188. Computer
analysis FOXC1 and SrCap amino acid sequences revealed
that these proteins were not related. Analysis of various
fragments of FOXC1, expressed as Gal4 fusion proteins,
Fig. 5. DBP disrupts the binding interaction of SrCap/CBP. CHO cells
were transfected as indicated with 100 ng of pGal-CAT reporter plasmid,
200 ng of a plasmid encoding Gal-CBP-(280–460) chimera (pGal-
CBP(280–460)), 200 ng of a plasmid encoding VP16-clone 11 chimera
(pVP16-SrCap), and the indicated amounts of a plasmid encoding Adeno-
virus DBP (pcDNA-DBP). The relative CAT enzymatic activity was de-
termined by dividing the CAT enzymatic activity of each sample by the
transcriptional activity induced by the Gal-CAT (which was assigned a
relative value of 1). Values represent the means  SE from at least three
separate experiments in which each sample was assayed in triplicate.
Fig. 4. DBP inhibits SrCap-activated Gal-CBP-mediated transcription.
CHO cells were transfected as indicated with 100 ng of pGal-CAT reporter
plasmid, 100 ng of a plasmid encoding a Gal-CBP chimera (pGal-CBP),
1000 ng of a plasmid encoding SrCap (pSrCap), and 250 ng of a plasmid
encoding Adenovirus DBP (pcDNA-DBP) as indicated. The relative CAT
enzymatic activity was determined by dividing the CAT enzymatic activity
of each sample by the transcriptional activity induced by the Gal-CBP
chimera (which was assigned a relative value of 1). Values represent the
means  SE from at least three separate experiments in which each sample
was assayed in triplicate.
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has mapped a strong transcriptional activation domain to
carboxyl-terminal amino acids 435–553 (Berry et al., 2002).
We have independently constructed a series of Gal4–
FOXC1 fusion protein and determined their abilities to
activate transcription from a GRE-containing CAT reporter
plasmid (V. Tarakanova and W.S.M. Wold, unpublished
results). We determined that one of these constructs, pGal-
FOXC1(amino acids 283–553), induced relative CAT ac-
tivity that was very similar to the amount that was induced
by Gal–SrCap (see Fig. 6). In the presence of a moderate
amount (150 ng) of the DBP expressing plasmid, the rela-
tive CAT activity induced by Gal-SrCap was dramatically
reduced to 24%. However, in the presence of a large amount
(500 ng) of the DBP-expressing plasmid the relative CAT
activity induced by Gal-FOXC1 was undiminished. This
result is consistent with our result that DBP also had no
significant inhibitory effect on another SrCap-independent
Gal construct, namely Gal-VP16 (Xu et al., 2001). Since the
Gal portions of the Gal-FOXC1 and Gal-SrCap fusion pro-
teins are identical, it suggests that DBP’s transcriptional
inhibition of Gal-SrCap-induced CAT activity is not acting
through an aberrant interaction between DBP and the Gal4
portion of the Gal–SrCap fusion protein. Rather, this data do
indicate that DBP’s inhibition of Gal–SrCap-induced CAT
activity is specific for the SrCap portion of the Gal-SrCap
fusion protein. In addition, since the CAT reporter plasmid
is the same in these assays, it suggests that DBP’s DNA
binding assay does not inhibit the CAT activity induced by
Gal-SrCap through a direct interaction with the CAT re-
porter plasmid.
While DBP is known to be cytotoxic (Klessig et al.,
1984), we do not observe cytopathic effects in these short-
term CAT assays. More interestingly, since we observe
DBP inhibition of SrCap-mediated transcription and not
inhibition of SrCap-independent transcription, it would sug-
gest that DBP preferentially targets cellular proteins, such as
SrCap, while in the presence of a vast excess of cellular
nucleic acid targets.
These data presented above suggest that, analogous to
the E1A proteins, which induce a portion of their transcrip-
tional repression activities through their interaction with
CBP and/or p300, DBP can inhibit transcription through its
interaction with SrCap. One apparent consequence of the
disruption of the SrCap–CBP interaction by DBP is that
PKA-activated CREB-mediated transcription is repressed.
Whether DBP has a similar role at all or a subset of host
promoters regulated by cAMP in the context of an Adeno-
viral infection is currently under investigation.
These findings suggest a model in which Adenovirus
expresses two viral gene products, DBP and E1A, that
disrupt the same cellular protein complex by targeting Sr-
Cap and CBP, respectively (see Fig. 7). The reason Adeno-
virus would redundantly target the SrCap–CBP interaction
and how this benefits the virus is not known. Since both
DBP and E1A can functionally and independently inhibit
transcription in the SrCap-CBP mammalian two-hybrid as-
say, it suggests that functional disruption of this cellular
interaction may be an important target for Adenovirus-
induced host cell regulation. We propose that the functional
disruption is due to a physical disruption of the SrCap–CBP
interaction. In this model, the binding of DBP to SrCap
disrupts the SrCap–CBP interaction and makes CBP more
accessible to E1A. We also speculate that this could enable
E1A to sequester CBP (and p300) to form a complex with
Fig. 6. DBP specifically inhibits SrCap-mediated transcription. CHO cells were transfected with the reporter plasmid pGal-CAT (100 ng), either pGal-SrCap
(500 ng) or pGal-FOXC1 (200 ng), with or without pcDNA-DBP (150 ng in the pGal-SrCap set or 500 ng in the pGal-FOXC1 set), as indicated. Transfections
were normalized to equal picomolar amounts of plasmid DNAs (using decreasing amounts of empty vector pcDNA) and to total amount of DNA (using
salmon sperm DNA). Values are the means  SE (error bars) from two separate experiments in which each point was performed in triplicate.
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Rb. This resulting complex formed between E1A, CBP (or
p300), and Rb has been shown to be essential for the
abilities of E1A proteins to fully activate the cell cycle
(Wang et al., 1995). In addition, in the E1A/CBP/p300/Rb
complex, the intrinsic CBP/p300 acetyltransferase activities
have been shown to acetylate Rb and regulate the ability of
Rb to form a protein–protein interaction with MDM2 (Chan
et al., 2001). In addition, since SrCap could no longer
coactivate CBP-mediated transcription, a portion of CBP-
mediated transcription of CBP-regulated cellular genes
would be repressed. Taken together, these results suggest an
intriguing DBP-mediated mechanism of host cell transcrip-
tional regulation.
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